(DCOY)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Decoy Therapeutics Inc. dori-darmonlarni ishlab chiqish va ishlab chiqarish murakkabligini kamaytiradigan Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platformasi orqali peptid kon'yugat terapiyasini rivojlantirishga qaratilgan. Uning IMP3ACT platformasi turli xil qondirilmagan tibbiy ehtiyojlarga mo'ljallangan peptid kon'yugatlarini ishlab chiqish, optimallashtirish va ishlab chiqarish uchun sintez usullaridan tashqari mashinani o'rganish va sun'iy intellekt vositalaridan foydalanadi. Kompaniya yuqumli kasalliklar va onkologiyaga qaratilgan peptid kon'yugat terapiyasini ishlab chiqishga e'tibor qaratadi. Kompaniya ilgari Salarius Pharmaceuticals, Inc. nomi bilan tanilgan va 2026-yil yanvar oyida Decoy Therapeutics Inc. nomini o'zgartirgan. Decoy Therapeutics Inc. Massachusets shtatining Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer & Director |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development |
| Mr. Frederick E. Pierce II | CEO & Director |
| Mr. Mark J. Rosenblum CPA | Executive VP & CFO |
| Mr. Peter K. Marschel M.B.A., M.S. | Chief Business Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-05 | 8-K | dcoy-20260305.htm |
| 2026-01-09 | DEF 14A | d70714ddef14a.htm |
| 2026-01-08 | 8-K | flks-20260108.htm |